Intelligence Squared Business Weekly: The Race for a Vaccine
Nov 29, 2021
Kate Bingham, former Chair of the UK Vaccine Taskforce and seasoned venture capitalist, shares her insights on the swift development of COVID-19 vaccines. She discusses how blending business expertise with scientific knowledge was crucial during the crisis. Bingham also dives into the challenges of rapid vaccine trials and the innovative solutions that emerged, including the establishment of a national citizen registry. Furthermore, she highlights the UK's proactive strategies for future pandemic preparedness and the role of AI in predicting viral mutations.
AI Snips
Chapters
Transcript
Episode notes
Adapting Existing Tech
- Despite a lack of human coronavirus vaccines, existing mRNA and adenovirus vaccine formats could be adapted.
- This allowed for rapid vaccine creation, with the Moderna vaccine designed and produced in just 42 days.
Concurrent Trials
- Cash availability allowed simultaneous safety testing and clinical trial recruitment, compressing the vaccine development timeline.
- This unusual approach involved financial risk but proved crucial for speed.
Industry Collaboration
- Oxford scientists sought help from the Bio-Industry Association to scale up vaccine production in February 2020.
- A coalition of contract manufacturers collaborated without contracts or payment, showcasing industry altruism.